Trials / Withdrawn
WithdrawnNCT01093677
Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance
A Single-Blind,Randomized,Placebo-Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Limerick BioPharma · Industry
- Sex
- Male
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose Tolerance
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LIM-0705 | Oral solution 750 mg LIM 0705 BID for 14 days. |
| DRUG | Placebo | Oral solution placebo BID for 14 days. |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2010-06-01
- Completion
- 2010-07-01
- First posted
- 2010-03-26
- Last updated
- 2010-06-08
Source: ClinicalTrials.gov record NCT01093677. Inclusion in this directory is not an endorsement.